Compare Lemonade Inc (LMND) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Lemonade IncTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Lemonade Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lemonade Inc trades at $68.99 (market cap $5.18B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.

	LMND	XBI
Market Cap	$5.18B	—
Sector	Financials	Broad Market / Factor
52-Week High	$96.57	$164.28
52-Week Low	$36.28	$85.16
Enterprise Value	$5.01B	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LMND

Lemonade launches affordable, tech-driven renters insurance in Nebraska starting at $5/month.PRNewsWire · 13 hours agoBullish Lemonade to report Q2 2026 earnings on July 29 with a conference call for investors.PRNewsWire · 5 days agoNeutral View details →

XBI

Healthcare ETFs lead State Street's top 5 performers with pharma fund gaining 11.7% in the past monthETF Trends · 4 days agoBullish View details →

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.